PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

May 20, 2010 | ISSUE NUMBER 148 VOL 8

Non-Profits
TB Alliance Trumpets New, Improved Drugs at World Health Assembly
Activist groups condemn governments for the lack of funding for TB and other neglected diseases. Will money issues halt this progress?

Legal
Novartis Employees Get $250 million Payout
A New York jury ruled in favor of female sales reps who claimed that the company fostered an atmosphere conducive to discrimination.

Mergers & Acquisitions
Astellas and OSI Come Together
The Japanese pharma giant finally signed a merger agreement with long sought-after OSI Pharmaceuticals, adding a new therapeutic area to its formidable arsenal.

Strategy
Judgment Day for Pfizer Factories
Eight manufacturing sites will be closed and put up for sale, and six more will see workforce cuts. Total damage: 6,000 workers.

Regulatory
New FDA Campaign Targets Detailing, Trade Shows
DDMAC’s “Bad Ads” program urges doctors to tattle about misleading presentations, off-label pitches.

// Cobalis’ board of directors elected Martin Marion CEO. // Former Pfizer CEO Hank McKinnell joined the board of Emmaus Medical. // Amgen’s board named Thomas Dittrich VP of finance and chief accounting officer. // Oramed Pharmaceuticals added Michael Berelowitz to its board. // ChemoCentryx president and CEO Thomas Schall was named Ernst & Young’s 2010 Entrepreneur of the Year.//

Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry. Download here

May 20 21 CFR Part 11, Computer Systems Validation and the Requirements of the FDA
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/csv

May 25 Moving Beyond Document Management to Enterprise Content Compliance
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/moving

May 24–27 Contract Lifecycle Management– I-many Summit 2010 User Conference
Miami, FL

June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC

Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA

Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy?

FDA Says GlaxoSmithKline's Rotarix Vaccine Is Safe

Health Insurance Companies Try to Shape Rules

Biogen, Roche Exit RA Drug Program Amid Risk of Fatal Infections

Follow Pharm Exec on Twitter

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.